Preclinical formulation for the pharmacokinetics and efficacy of GBO-006, a selective polo like kinase 2 (PLK2) inhibitor for the treatment of triple negative breast cancer. ADMET DMPK [Internet]. 2016 Dec. 26 [cited 2025 Oct. 30];4(4):314-26. Available from: https://pub.iapchem.org/ojs/index.php/admet/article/view/341